trending Market Intelligence /marketintelligence/en/news-insights/trending/E7uqo36lgmpSg5LDpfYCjA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA keeps clinical hold on Regulus hepatitis C drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA keeps clinical hold on Regulus hepatitis C drug

The U.S. FDA kept its clinical hold on Regulus Therapeutics Inc.'s clinical development program for RG-101 for the treatment of hepatitis C virus.

The drug was placed on clinical hold in June 2016 after Regulus' submission of a second serious adverse event of jaundice.

Regulus submitted a complete response to the FDA's initial request for information in 2016, which included identification of a potential mechanism of hyperbilirubinemia. It also submitted a proposal to mitigate this risk.

Subsequently, the FDA requested the final safety and efficacy data from ongoing clinical and pre-clinical studies for the drug before reconsidering the clinical hold. The FDA also requested additional expert review of liver safety data due to the proposed mechanism of hyperbilirubinemia.